• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
NOX

NOXOPHARM LIMITED - News & Media

9.09% ! 12.0¢
Market Cap $35.06M  !
Healthcare Biotechnology
Add to My Watchlist

Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel... Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Articles & Videos

Noxopharm gets HERACLES autoimmune trials started with first human doses

Noxopharm Ltd (ASX:NOX) has got its HERACLES trials out the gates in Week 29, dosing a preliminary patient in the first-in-human use of its SOF-SKN topical drug candidate targeting TLR7/8 for autoimmune diseases.Listen to the HotCopper podcast for in-depth discussions and insights on all the bigg...

16 Jul 2025 11:19 (AEST)

Noxopharm jumps as flagship lupus drug clears first-pass in vitro safety tests

Noxopharm has reported its lupus medication in development, SOF-SKN, has passed first-stage in vitro safety tests before clinical trials.

04 Feb 2025 10:30 (AEDT)

Noxopharm aims for autoimmune market with first human trial of SOF-SKN

Noxopharm Ltd is planning the first human trial to assess novel drug SOF-SKN, which aims to treat autoimmune conditions.

19 Aug 2024 11:36 (AEST)

Noxopharm jumps 35% on news its drug CRO-67 reduced human pancreatic tumour cells in mice

Shares in Noxopharm (ASX:NOX) jumped nearly 40% in morning trades on Wednesday as the company announced its experimental drug CRO-67 reduced human pancreatic tumour cells implanted into mice.

14 Aug 2024 11:16 (AEST)

Noxopharm (ASX:NOX) publishes preliminary data from phase one Veyonda trial

Aussie biotech company Noxopharm (NOX) has wrapped up its IONIC investigator-initiated pilot for its oncology drug Veyonda.

26 May 2023 15:19 (AEST)

Noxopharm (ASX:NOX) narrows focus on “cutting-edge” Chroma and Sofra programs

NSW-based biotech company Noxopharm (ASX:NOX) has announced its decision to prioritise the development of its two "cutting-edge" preclinical technology platforms moving forward – Chroma and Sofra.

06 Apr 2023 10:45 (AEST)

Noxopharm (ASX:NOX) announces novel mRNA "vaccine enhancer" product

Biotech company Noxopharm (ASX:NOX) has created an mRNA "vaccine enhancer" to improve the effectiveness of vaccines and reduce inflammation.

28 Mar 2023 12:26 (AEDT)

Noxopharm (ASX:NOX) receives green light to progress DARRT-2 trial

Noxopharm (ASX:NOX) is set to progress to part two of its clinical trial of its drug candidate Veyonda to treat prostate cancer.

17 Jan 2023 10:35 (AEDT)



Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist
(20min delay)
Last
12.0¢ 		Change
0.010(9.09%) 		Mkt cap ! $35.06M
Open High Low Value Volume
12.0¢ 13.5¢ 11.5¢ $163.9K 1.289M

Buyers (Bids)

No. Vol. Price($)
4 122326 11.5¢
 

Sellers (Offers)

Price($) Vol. No.
12.0¢ 65828 2
View Market Depth
Last trade - 14.29pm 11/08/2025 (20 minute delay) ?
Last
11.5¢ 		  Change
0.010 ( 0.00 %)
Open High Low Volume
12.0¢ 13.5¢ 11.5¢ 541896
Last updated 14.37pm 11/08/2025 ?
NOX (ASX) Chart

Top Stories

Trump's not talking about Greenland – so why is ETM up +130%?

Sixty Minutes is, in many ways, peak boomer. The not-so-shiny-anymore crown jewel of a media brand now more invested in property...
DroneShield's civilian counter-drone tech lands with a buzz A silent guardian, standing tall and watching the skies. No, it’s not a superhero, but DroneShield’s (ASX:DRO) newest brainchild, SentryCiv: A new subscription-based counter-drone system for the civilian market.Listen to the HotCopper podcast for in-depth discussio...
Can the market squeeze IDP Education's shorters? As of Week 33, it looks possible IDP Education (ASX:IEL), a company that ultimately trains up foreign students moving to Australia, has long been one of the most...
The cash flow on demand strategy that works This week on Money and Investing, Mitch Olarenshaw and I break down the strategy behind Cash Flow on Demand @ a proven system for generating consistent income from the sharemarket with lower risk.1. The cash flow on demand strategyThis income strategy has been our flagship approach at Australian ...
Monday's HotCopper trends: DRO civ counterdrone, Dateline drill hits | Aug 11 DroneShield (ASX:DRO) has captured the most attention across the HotCopper forums through Week 33’s first trade day, sparking excitement with its new @SentryCiv,” a subscription-based AI counterdrone solution.Listen to the HotCopper podcast for in-depth discu...
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.